US Government Approves NVIDIA H200 Chip Sales to 10 Chinese Firms
The US Department of Commerce granted export licenses allowing NVIDIA to sell advanced H200 chips to Chinese companies, marking a rare regulatory win for the semiconductor giant after months of export restrictions. The move signals tactical coordination between semiconductor policy and trade diplomacy ahead of the Trump-Xi summit.
RKey facts
- US government approved NVIDIA H200 chip sales to 10 Chinese companies
- H200 is advanced AI inference accelerator; prior export ban was near-total
- Approval coincides with Trump-Xi summit trade negotiations
- Trump personally holds over $1M in NVIDIA shares
What's happening
US government approval for NVIDIA to sell H200 chips to ten Chinese companies emerged as a significant policy reversal on May 14. This followed months of strict export controls designed to starve Chinese AI development of cutting-edge US silicon. The timing, coinciding with the Trump-Xi summit in Beijing, suggests the licences were granted as part of broader trade negotiations to ease tensions.
NVIDA's stock rallied over the development, extending gains from a broader AI infrastructure rally. The H200, a specialized accelerator chip optimized for AI inference and large language model deployment, has been central to global data center buildouts. Chinese tech giants and state-backed AI initiatives had been lobbying Washington to ease restrictions, arguing that blanket bans were ineffective and economically punitive to US chipmakers seeking market share.
The export approval is significant because it reflects a shift in US policy framing: instead of treating all advanced chip sales to China as security threats, the administration appears willing to carve out narrow windows for specific customers and use-cases if it yields trade concessions elsewhere (agricultural purchases, for example). NVIDIA's stock response was swift; the company has over $1 million in holdings in Trump's personal portfolio, which may have influenced the tone of public statements from his trade team.
Bears argue that allowing the H200 to reach Chinese AI labs will accelerate their capability parity with US firms within 18-24 months, undercutting the long-term rationale for export controls. Supporters counter that a more flexible licensing regime keeps NVIDIA's revenue intact and maintains industry relationships that stricter bans would have permanently damaged. The debate hinges on whether this is a one-off concession or signals a broader normalization of US-China semiconductor trade.
What to watch next
- 01NVIDIA's next quarterly guidanceCompany-issued forecasts of future financial performance. on China revenue exposure
- 02Further US chip export licence approvals; scope of relaxation
- 03Chinese AI lab benchmarks; speed of capability gains
- PR Newswire FinancialEightco Holdings (NASDAQ: ORBS) dichiara un portafoglio complessivo di circa 340 milioni di dollari, che comprende OpenAI, Beast Industries, oltre 11.000 ETH e più di 283 milioni di token WLD
Composizione della tesoreria di Eightco al 12 maggio 2026: 90 milioni di dollari in azioni OpenAI (indirette), 18 milioni di dollari in azioni Beast Industries, 11.068 ETH, 283 milioni di WLD e 129 milioni di dollari in contanti e mezzi equivalenti, per un totale di circa 340 milioni di...
37m ago - PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Willis Towers Watson plc - WTW
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Willis Towers Watson plc ("Willis Towers Watson" or the "Company") (NASDAQ: WTW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
3h ago - PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blaize Holdings, Inc. - BZAI
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Blaize Holdings, Inc. ("Blaize" or the "Company") (NASDAQ: BZAI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
3h ago - PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Meridian Corporation - MRBK
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Meridian Corporation ("Meridian" or the "Company") (NASDAQ: MRBK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
3h ago - PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of JetBlue Airways Corporation - JBLU
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of JetBlue Airways Corporation ("JetBlue" or the "Company") (NASDAQ: JBLU). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
3h ago - PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
3h ago - PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sportradar Group AG - SRAD
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sportradar Group AG ("Sportradar" or the "Company") (NASDAQ: SRAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
3h ago - PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grace Therapeutics, Inc. ("Grace" or the "Company") (NASDAQ: GRCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
3h ago
Related coverage
- S&P 500 Mega-Cap Concentration at Record; 7 Stocks Drive 90% of YTD GainsTech & AI··0 mentions
- U.S. Lifts NVIDIA China Restrictions, Restoring 25% of Revenue PipelineTech & AI··0 mentions
- S&P 500 and Nasdaq Hit Fresh Records Amid AI Momentum; Breadth Deteriorates as Mega-Cap Dominance PersistsTech & AI··0 mentions
- Cerebras IPO Raises $5.55B, Exceeds Estimates; AI Chip Euphoria Broadens Beyond NVDATech & AI··0 mentions
More about $NVDA
- S&P 500 Mega-Cap Concentration at Record; 7 Stocks Drive 90% of YTD Gains·Tech & AI
- U.S. Lifts NVIDIA China Restrictions, Restoring 25% of Revenue Pipeline·Tech & AI
- S&P 500 and Nasdaq Hit Fresh Records Amid AI Momentum; Breadth Deteriorates as Mega-Cap Dominance Persists·Tech & AI
- US Lifts China Chip Export Restrictions, NVDA 25% Revenue Exposure Unlocked·Tech & AI
- Cerebras IPO Raises $5.55B, Exceeds Estimates; AI Chip Euphoria Broadens Beyond NVDA·Tech & AI
Tracking AI infrastructure capex — hyperscaler spend, data center buildouts, memory demand and the margin compression risk.